Denver Newsroom, Apr 29, 2020 / 19:30 pm
The numbers of women seeking at-home medication abortions through an experimental U.S. telemedicine provider has reportedly doubled under the coronavirus epidemic, though pro-life advocates said there are good reasons for restrictions on the practice.
“Unfortunately women are being influenced by fear right now, and this is being perpetuated by the abortion industry,” Dr. Christina Francis, an Indiana-based OB/GYN and chairman of the board of the American Association of Pro-Life OBGYNs, told EWTN Pro-Life Weekly April 23.
“Certainly all of us are facing uncertain circumstances,” Francis said. “There are a lot of women out there who find themselves pregnant and are not sure what they are going to do. Maybe they are facing the fact that they don’t have a job or they are struggling to put food on the table. But this is not a reason why we should push women into abortions.”
The New York-based Gynuity Health Products is the sponsor of the TelAbortion telemedicine-style abortion project now active in 13 states.
“The ability to get abortion medications from a health care provider by mail is particularly crucial in the COVID-19 crisis,” Gynuity said on Twitter April 29. The organization’s website describes its mission as a development and advocacy group in reproductive and maternal health.
Gynuity’s TelAbortion project reports that, excluding Illinois and Maryland, which are new to the program, the numbers of women seeking abortions through TelAbortion doubled in March and April compared to January and February, the New York Times reported in its April 28 profile of the project and of several women who used it.
The coronavirus epidemic has meant strict stay-at-home orders in many states. Fearing a shortage of medical resources, authorities barred elective surgeries, and some states include elective abortions in the ban.
Francis warned of a push to lift restrictions surrounding medication abortions dispensed by telemedicine methods.